NZ579227A - Methods of identifying activators of lyn kinase - Google Patents
Methods of identifying activators of lyn kinaseInfo
- Publication number
- NZ579227A NZ579227A NZ579227A NZ57922708A NZ579227A NZ 579227 A NZ579227 A NZ 579227A NZ 579227 A NZ579227 A NZ 579227A NZ 57922708 A NZ57922708 A NZ 57922708A NZ 579227 A NZ579227 A NZ 579227A
- Authority
- NZ
- New Zealand
- Prior art keywords
- lyn kinase
- methods
- substrate
- test compound
- identifying activators
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 5
- 102000020233 phosphotransferase Human genes 0.000 title abstract 5
- 239000012190 activator Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000758 substrate Substances 0.000 abstract 4
- 230000026731 phosphorylation Effects 0.000 abstract 2
- 238000006366 phosphorylation reaction Methods 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89063207P | 2007-02-20 | 2007-02-20 | |
| PCT/US2008/054361 WO2008103692A2 (en) | 2007-02-20 | 2008-02-20 | Methods of identifying activators of lyn kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ579227A true NZ579227A (en) | 2012-11-30 |
Family
ID=39710712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ579227A NZ579227A (en) | 2007-02-20 | 2008-02-20 | Methods of identifying activators of lyn kinase |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100152215A1 (enExample) |
| EP (1) | EP2120581A4 (enExample) |
| JP (1) | JP2010518860A (enExample) |
| KR (1) | KR20100014480A (enExample) |
| CN (1) | CN101686686A (enExample) |
| AU (1) | AU2008218765A1 (enExample) |
| BR (1) | BRPI0807928A2 (enExample) |
| CA (1) | CA2678813A1 (enExample) |
| IL (1) | IL200429A0 (enExample) |
| MX (1) | MX2009008874A (enExample) |
| NZ (1) | NZ579227A (enExample) |
| WO (1) | WO2008103692A2 (enExample) |
| ZA (1) | ZA200905776B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB201010196D0 (en) * | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| CN102507707B (zh) * | 2011-10-12 | 2015-10-21 | 山东大学 | 一种检测龈沟液中蛋白裂解酶含量的方法 |
| CN104271140B (zh) * | 2011-12-12 | 2016-11-23 | 梅里奥尔医药I公司 | I型和ii型糖尿病的治疗 |
| US9827222B2 (en) * | 2013-07-01 | 2017-11-28 | Emory University | Treating or preventing nephrogenic diabetes insipidus |
| WO2015099094A1 (ja) | 2013-12-27 | 2015-07-02 | 国立大学法人東京医科歯科大学 | アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法 |
| AU2019223911A1 (en) * | 2018-02-21 | 2020-07-23 | Melior Pharmaceuticals I, Inc. | Treatment of liver diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US3922345A (en) * | 1971-10-29 | 1975-11-25 | Pfizer | Pyrimidinones and hydroxy pyrimidines |
| US4080454A (en) * | 1976-07-16 | 1978-03-21 | Pfizer Inc. | 5-M-Tolyloxyuracil, anti-ulcer agent |
| US4612376A (en) * | 1983-03-25 | 1986-09-16 | Fujisawa Pharmaceutical Co., Ltd. | Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent |
| US5698155A (en) * | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| SE9203753D0 (sv) * | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| US5476855A (en) * | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
| US6900304B2 (en) * | 1996-01-31 | 2005-05-31 | The Regents Of The University Of California | Emission ratiometric indicators of phosphorylation |
| US20020019346A1 (en) * | 1997-05-21 | 2002-02-14 | Children's Medical Center Corporation | Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
| US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6410255B1 (en) * | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
| GB0104422D0 (en) * | 2001-02-22 | 2001-04-11 | Glaxo Group Ltd | Quinoline derivative |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| EP1618094B1 (en) * | 2003-04-30 | 2007-09-05 | The Institutes for Pharmaceutical Discovery, LLC | Substituted heteroaryls as inhibitors of protein tyrosine phosphatases |
| EP1541694A1 (en) * | 2003-12-12 | 2005-06-15 | Sirenade Pharmaceuticals AG | Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase |
| US20060035302A1 (en) * | 2004-06-21 | 2006-02-16 | Applera Corporation | Kinase substrates with multiple phosphorylation sites |
| JP2008521900A (ja) * | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| ITUD20050112A1 (it) * | 2005-07-01 | 2007-01-02 | Gaetano Azzolina | Dispositivo di assistenza cardiocircolatoria |
| TWI273177B (en) * | 2005-07-08 | 2007-02-11 | Ama Precision Inc | Fan apparatus with adapting device |
| WO2007016975A1 (en) * | 2005-07-29 | 2007-02-15 | F. Hoffmann-La Roche Ag | Kinase and phosphatase assays based on fret |
| NZ565955A (en) * | 2005-08-22 | 2011-08-26 | Melior Pharmaceuticals I Inc | Methods and formulations for modulating lyn kinase activity and treating related disorders |
| US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
-
2008
- 2008-02-20 AU AU2008218765A patent/AU2008218765A1/en not_active Abandoned
- 2008-02-20 NZ NZ579227A patent/NZ579227A/xx not_active IP Right Cessation
- 2008-02-20 BR BRPI0807928-5A patent/BRPI0807928A2/pt not_active IP Right Cessation
- 2008-02-20 KR KR1020097019560A patent/KR20100014480A/ko not_active Withdrawn
- 2008-02-20 EP EP08730208A patent/EP2120581A4/en not_active Withdrawn
- 2008-02-20 CN CN200880012768A patent/CN101686686A/zh active Pending
- 2008-02-20 US US12/527,801 patent/US20100152215A1/en not_active Abandoned
- 2008-02-20 JP JP2009550979A patent/JP2010518860A/ja active Pending
- 2008-02-20 MX MX2009008874A patent/MX2009008874A/es not_active Application Discontinuation
- 2008-02-20 CA CA002678813A patent/CA2678813A1/en not_active Abandoned
- 2008-02-20 WO PCT/US2008/054361 patent/WO2008103692A2/en not_active Ceased
-
2009
- 2009-08-17 IL IL200429A patent/IL200429A0/en unknown
- 2009-08-19 ZA ZA200905776A patent/ZA200905776B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2120581A4 (en) | 2011-03-16 |
| MX2009008874A (es) | 2009-10-20 |
| CN101686686A (zh) | 2010-03-31 |
| ZA200905776B (en) | 2010-05-26 |
| JP2010518860A (ja) | 2010-06-03 |
| EP2120581A2 (en) | 2009-11-25 |
| WO2008103692A2 (en) | 2008-08-28 |
| AU2008218765A1 (en) | 2008-08-28 |
| US20100152215A1 (en) | 2010-06-17 |
| BRPI0807928A2 (pt) | 2014-07-08 |
| IL200429A0 (en) | 2010-04-29 |
| CA2678813A1 (en) | 2008-08-28 |
| WO2008103692A3 (en) | 2008-10-23 |
| KR20100014480A (ko) | 2010-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ579227A (en) | Methods of identifying activators of lyn kinase | |
| NZ745469A (en) | Reagent materials and associated test elements | |
| PH12013500240A1 (en) | Biomarker assays for detecting or measuring inhibition of tor kinase activity | |
| TN2010000131A1 (en) | Polo-like kinase inhibitors | |
| ZA200808536B (en) | Deazapurines useful as inhibitors of janus kinases | |
| PH12012502017A1 (en) | Predictive markers useful in the treatment of fragile x syndrome (fxs) | |
| WO2011097301A3 (en) | METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR | |
| EP4585589A3 (en) | Stem cell cultures | |
| MX2008013582A (es) | Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa. | |
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| MX2011013385A (es) | Metodos para cultivar celulas madre y celulas progenitoras. | |
| MY146989A (en) | Kinase inhibitors | |
| WO2011153553A3 (en) | Methods and compositions for kinase inhibition | |
| PH12012502485A1 (en) | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | |
| PH12014500373A1 (en) | Amino quinazolines as kinase inhibitors | |
| MX2009006675A (es) | Inhibidores de cinasa mpk/erk. | |
| MY155719A (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| MX2010003154A (es) | Metodo y aparato para el tratamiento de desperdicio organico. | |
| CR20140128A (es) | Inhibidores de la enzima activadora de nedd 8 | |
| WO2009055823A3 (en) | Method to predict responsiveness of breast cancer to polyaminetype chemotherapy | |
| WO2012027266A3 (en) | Methods for dectecting embryonic stem cells, induced pluripotent stem cells, or cells undergoing reprogramming to produce induced pluripotent stem cells | |
| MX2010008407A (es) | Desactivacion de una composicion explosiva utilizando enzimas. | |
| CY1118495T1 (el) | Συνθεσεις συνδυασμου αγωνιστων α1 αδενοσινης και αναστολεων ανθρακικης ανυδρασης για μειωση της ενδοφθαλμιας πιεσης | |
| GB201021509D0 (en) | Assay method | |
| MY149500A (en) | The quantitative determination of risedronate in urine by spe-lc-ms-ms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 FEB 2015 BY FB RICE Effective date: 20130516 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 FEB 2016 BY COMPUTER PACKAGES INC Effective date: 20150131 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 FEB 2017 BY COMPUTER PACKAGES INC Effective date: 20160218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 FEB 2018 BY COMPUTER PACKAGES INC Effective date: 20170218 |
|
| LAPS | Patent lapsed |